# \[e-drug\] Independent Drug and Healthcare Newsletter for November 2020
**URL:** https://talk.edrugplus.org/t/e-drug-independent-drug-and-healthcare-newsletter-for-november-2020/46063
**Category:** e-drug
**Created:** [November 2, 2020, 9:44am UTC](https://talk.edrugplus.org/t/e-drug-independent-drug-and-healthcare-newsletter-for-november-2020/46063 "2020-11-02T09:44:33Z")
**Posts on this page:** 2
**Page:** 1
### Author:  [@international](https://talk.edrugplus.org/u/international)
#### Post date: [November 2, 2020, 9:44am UTC](https://talk.edrugplus.org/t/e-drug-independent-drug-and-healthcare-newsletter-for-november-2020/46063/1 "2020-11-02T09:44:33Z")
E=DRUG: Independent Drug and Healthcare Newsletter for November 2020
-------------------------------------------------------------------------
Newsletter, November 2020
Independant information by and for healthcare professionals
View the contents
[http://english.prescrire.org/en/SummaryDetail.aspx?Issueid=220](http://english.prescrire.org/en/SummaryDetail.aspx?Issueid=220)
If your friends or colleagues would be interested, forward this email and invite them to sign up for the free Newsletter.
[http://english.prescrire.org/en/83/552/0/0/About.aspx](http://english.prescrire.org/en/83/552/0/0/About.aspx)
Like what you see?
Subscribe to Prescrire International : [http://english.prescrire.org/en/83/178/0/0/About.aspx](http://english.prescrire.org/en/83/178/0/0/About.aspx)
In Prescrire's Spotlight this month:
Doxylamine during pregnancy: minimise dose and duration, due to possible link with malformations
Prescrire's analyses have for many years found doxylamine to be the first-choice antiemetic drug in early pregnancy, when non-pharmacological measures fail. A recent study suggests an increased risk of major birth defects. Does this finding affect doxylamine's harm-benefit balance and its place as the first-choice drug for relieving nausea and vomiting during pregnancy?
Read more
[https://english.prescrire.org/en/81/168/60220/0/NewsDetails.aspx](https://english.prescrire.org/en/81/168/60220/0/NewsDetails.aspx)
----------------------------------------------------------------------------
In the November issue of Prescrire International: Dupilumab (Dupixent°) and nasal polyps
Dupilumab (Dupixent°) has been authorised in the European Union for adults with very troublesome nasal polyposis. How do Prescrire's editors rate dupilumab in this situation?
Read more
[https://english.prescrire.org/en/81/168/60221/0/NewsDetails.aspx](https://english.prescrire.org/en/81/168/60221/0/NewsDetails.aspx)
----------------------------------------------------------------------------
EDITORIAL
Memory can save lives
In the field of pharmaceuticals, novelty is not always what it seems. It is often useful to remember the chemical relationships between substances, in order to predict certain beneficial or adverse effects.
Read more
[https://english.prescrire.org/en/81/168/60219/0/NewsDetails.aspx](https://english.prescrire.org/en/81/168/60219/0/NewsDetails.aspx)
----------------------------------------------------------------------------
NEW PRODUCTS
Dapagliflozin (Forxiga°): no place in type 1 diabetes
Dapagliflozin (Forxiga°) has no demonstrated efficacy with regard to the clinical complications of type 1 diabetes and it carries a risk of sometimes serious adverse effects.
Read more
[https://english.prescrire.org/en/81/168/60224/0/NewsDetails.aspx](https://english.prescrire.org/en/81/168/60224/0/NewsDetails.aspx)
----------------------------------------------------------------------------
OUTLOOK
Clinical trials of drugs: the various types of placebo used
In certain situations, the best way of telling the extent to which a treatment's apparent effects are due to the natural history of the disease or the treatment itself is to compare it with a placebo.
Read more
[https://english.prescrire.org/en/81/168/60223/0/NewsDetails.aspx](https://english.prescrire.org/en/81/168/60223/0/NewsDetails.aspx)
----------------------------------------------------------------------------
COMING SOON
Enjoy these features, and more, in our upcoming issues
Fexinidazole and sleeping sickness \* Betibeglogene autotemcel in certain forms of beta thalassaemia \* Drug-induced pericarditis \* Bimatoprost eye drops: enophthalmos \* Relief of nociceptive pain in breastfeeding women \* Drugs: public funding for research, private profits...
Subscribe now
[https://english.prescrire.org/en/83/178/0/0/About.aspx](https://english.prescrire.org/en/83/178/0/0/About.aspx)
Prescrire International \
---
### Author:  [@LiliyaEZ](https://talk.edrugplus.org/u/LiliyaEZ)
#### Post date: [November 3, 2020, 6:38am UTC](https://talk.edrugplus.org/t/e-drug-independent-drug-and-healthcare-newsletter-for-november-2020/46063/2 "2020-11-03T06:38:06Z")
Independent Drug and Healthcare Newsletter for November 2020
-------------------------------------------------------------------------
Newsletter, November 2020
Independent information by and for healthcare professionals
View the contents
[http://english.prescrire.org/en/SummaryDetail.aspx?Issueid=220](http://english.prescrire.org/en/SummaryDetail.aspx?Issueid=220)
If your friends or colleagues would be interested, forward this email and
invite them to sign up for the free Newsletter.
[http://english.prescrire.org/en/83/552/0/0/About.aspx](http://english.prescrire.org/en/83/552/0/0/About.aspx)
Like what you see?
Subscribe to Prescrire International :
[http://english.prescrire.org/en/83/178/0/0/About.aspx](http://english.prescrire.org/en/83/178/0/0/About.aspx)
In Prescrire's Spotlight this month:
Doxylamine during pregnancy: minimise dose and duration, due to possible
link with malformations
Prescrire's analyses have for many years found doxylamine to be the
first-choice antiemetic drug in early pregnancy, when non-pharmacological
measures fail. A recent study suggests an increased risk of major birth
defects. Does this finding affect doxylamine's harm-benefit balance and its
place as the first-choice drug for relieving nausea and vomiting during
pregnancy?
Read more
[https://english.prescrire.org/en/81/168/60220/0/NewsDetails.aspx](https://english.prescrire.org/en/81/168/60220/0/NewsDetails.aspx)
----------------------------------------------------------------------------
In the November issue of Prescrire International: Dupilumab (Dupixent°) and
nasal polyps
Dupilumab (Dupixent°) has been authorised in the European Union for adults
with very troublesome nasal polyposis. How do Prescrire's editors rate
dupilumab in this situation?
Read more
[https://english.prescrire.org/en/81/168/60221/0/NewsDetails.aspx](https://english.prescrire.org/en/81/168/60221/0/NewsDetails.aspx)
----------------------------------------------------------------------------
EDITORIAL
Memory can save lives
In the field of pharmaceuticals, novelty is not always what it seems. It is
often useful to remember the chemical relationships between substances, in
order to predict certain beneficial or adverse effects.
Read more
[https://english.prescrire.org/en/81/168/60219/0/NewsDetails.aspx](https://english.prescrire.org/en/81/168/60219/0/NewsDetails.aspx)
----------------------------------------------------------------------------
NEW PRODUCTS
Dapagliflozin (Forxiga°): no place in type 1 diabetes
Dapagliflozin (Forxiga°) has no demonstrated efficacy with regard to the
clinical complications of type 1 diabetes and it carries a risk of
sometimes serious adverse effects.
Read more
[https://english.prescrire.org/en/81/168/60224/0/NewsDetails.aspx](https://english.prescrire.org/en/81/168/60224/0/NewsDetails.aspx)
----------------------------------------------------------------------------
OUTLOOK
Clinical trials of drugs: the various types of placebo used
In certain situations, the best way of telling the extent to which a
treatment's apparent effects are due to the natural history of the disease
or the treatment itself is to compare it with a placebo.
Read more
[https://english.prescrire.org/en/81/168/60223/0/NewsDetails.aspx](https://english.prescrire.org/en/81/168/60223/0/NewsDetails.aspx)
----------------------------------------------------------------------------
COMING SOON
Enjoy these features, and more, in our upcoming issues
Fexinidazole and sleeping sickness \* Betibeglogene autotemcel in certain
forms of beta thalassaemia \* Drug-induced pericarditis \* Bimatoprost eye
drops: enophthalmos \* Relief of nociceptive pain in breastfeeding women \*
Drugs: public funding for research, private profits...
Subscribe now
[https://english.prescrire.org/en/83/178/0/0/About.aspx](https://english.prescrire.org/en/83/178/0/0/About.aspx)
Prescrire International \